---
title: "Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286904596.md"
description: "Definium has released an updated corporate presentation detailing its Phase 3 DT120 ODT program, with three topline readouts expected in 2026. The company reported $373.4 million in cash and equivalents as of March 31, 2026, with a cash runway projected into 2028. The presentation also highlights Phase 2b results showing effective single-dose outcomes in GAD and MDD, and ongoing Phase 2a studies for DT402 (R(-)-MDMA)."
datetime: "2026-05-19T11:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286904596.md)
  - [en](https://longbridge.com/en/news/286904596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286904596.md)
---

# Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash

**Definium posted an updated corporate presentation highlighting Phase 3 DT120 ODT program, upcoming topline readouts in 2026 and $373.4 million in cash, cash equivalents and investments.**

**Key Highlights:**

-   Updated May 2026 corporate presentation filed as Exhibit 99.1 and posted on company website.
-   DT120 ODT: lead program with five Phase 3 studies; three Phase 3 topline readouts expected in 2026 (Emerge, Voyage, Panorama).
-   Reported cash, cash equivalents and investments of $373.4M as of March 31, 2026; cash runway expected into 2028 per company plan.
-   Phase 2b results cited: rapid, durable single-dose effects in GAD and MDD with favorable tolerability supporting Phase 3 design.
-   DT402 (R(-)-MDMA) completed Phase 1; Phase 2a in ASD underway with initial data anticipated in 2026.

Original SEC Filing: Definium Therapeutics, Inc. \[ DFTX \] - 8-K - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [Watch live: Rethinking Psychedelic Treatment for America's Mental Health Crisis](https://longbridge.com/en/news/286901819.md)
- [ASP Releases Updated Investor Presentation, Notes Forward-Looking Statements](https://longbridge.com/en/news/287122849.md)
- [Federal Signal posts May 2026 investor presentation, raises 2026 outlook and margin targets](https://longbridge.com/en/news/287104853.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [Athene posts fixed-income investor presentation for May 15, 2025 call](https://longbridge.com/en/news/286560329.md)